US Bancorp DE Acquires 3,764 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

US Bancorp DE increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 14.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,343 shares of the pharmaceutical company's stock after purchasing an additional 3,764 shares during the quarter. US Bancorp DE's holdings in Vertex Pharmaceuticals were worth $12,219,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of VRTX. Dunhill Financial LLC lifted its holdings in shares of Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company's stock worth $27,000 after acquiring an additional 24 shares during the period. Brown Lisle Cummings Inc. bought a new stake in Vertex Pharmaceuticals during the fourth quarter worth $30,000. Legacy Investment Solutions LLC bought a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at $33,000. Truvestments Capital LLC acquired a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth $35,000. Finally, Sugar Maple Asset Management LLC bought a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth $35,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total value of $111,034.64. Following the transaction, the executive vice president now directly owns 67,695 shares of the company's stock, valued at approximately $30,805,286.70. This trade represents a 0.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 1,084 shares of company stock worth $505,512 in the last ninety days. Corporate insiders own 0.20% of the company's stock.

Wall Street Analyst Weigh In

VRTX has been the subject of several research analyst reports. UBS Group boosted their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Morgan Stanley upped their price objective on shares of Vertex Pharmaceuticals from $450.00 to $459.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 11th. Truist Financial raised their target price on shares of Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a "buy" rating in a research report on Tuesday, February 11th. Piper Sandler lowered their price target on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an "overweight" rating for the company in a report on Monday, January 27th. Finally, StockNews.com downgraded Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Wednesday, February 19th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $506.70.

Vertex Pharmaceuticals Stock Up 1.3 %

Shares of Vertex Pharmaceuticals stock traded up $6.09 during trading on Wednesday, reaching $492.31. 506,137 shares of the company traded hands, compared to its average volume of 1,479,976. The firm has a market capitalization of $126.42 billion, a PE ratio of -223.84, a P/E/G ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The company has a 50 day moving average price of $443.51 and a 200-day moving average price of $461.12. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.